会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 32. 发明授权
    • Print-document conversion apparatus, print-document conversion method, and computer-readable medium storing program
    • 打印文档转换装置,打印文档转换方法和计算机可读介质存储程序
    • US08576435B2
    • 2013-11-05
    • US12903678
    • 2010-10-13
    • Koichi Miyazaki
    • Koichi Miyazaki
    • G06F3/12G06K15/00G06K15/22G06K9/34G06K9/54
    • G06F3/1288G06F3/1211G06F3/122G06F3/124G06F3/1245G06F3/1247G06K15/1857
    • A print-document conversion apparatus includes a conversion-module activation section that activates, as a process, a conversion module for performing conversion processing for converting print-document data which is described in a page description language and which includes units of processing into print-image data. The conversion module includes a thread activation part, an assigning part, and a shared cache. The thread activation part activates conversion processing threads. The assigning part assigns the units of processing to the conversion processing threads, and causes the conversion processing threads to perform processing on the units of processing. The shared cache is shared by the conversion processing threads. When a conversion result obtained by converting an object included in the units of processing is stored in the shared cache, each of the conversion processing threads obtains the stored conversion result instead of obtaining the conversion result by converting the object.
    • 一种打印文档转换装置,包括转换模块激活部件,其作为处理激活转换模块,该转换模块用于执行转换处理,用于将以页面描述语言描述的打印文档数据转换为打印文档数据, 图像数据。 转换模块包括线程激活部分,分配部分和共享高速缓存。 线程激活部分激活转换处理线程。 分配部分将处理单位分配给转换处理线程,并使转换处理线程对处理单元执行处理。 共享缓存由转换处理线程共享。 当通过将包含在处理单元中的对象转换得到的转换结果存储在共享高速缓存中时,每个转换处理线程获得所存储的转换结果,而不是通过转换对象来获得转换结果。
    • 37. 发明申请
    • Image processing device, image output device, terminal device, and image forming system and computer readable medium storing program thereof
    • 图像处理装置,图像输出装置,终端装置,图像形成系统及其计算机可读介质存储程序
    • US20080055678A1
    • 2008-03-06
    • US11723024
    • 2007-03-15
    • Koichi Miyazaki
    • Koichi Miyazaki
    • G06K15/22
    • H04N1/58H04N1/6008H04N1/6072
    • An image processing device includes a separation unit that separates image information including a first image having plural color components and a second image having a specific color component and to be overlaid at least in part on the first image into a specific color component image of the same color component as the specific color component and an image with color components other than the specific color component among the plural color components; a color conversion unit that performs color conversion of the image with color components other than the specific color component, separated by the separation unit; and a combination unit that combines the color-converted image with color components other than the specific color component, converted by the color conversion unit, and the specific color component image separated by the separation unit.
    • 图像处理装置包括:分离单元,其分离包括具有多个颜色分量的第一图像的图像信息和具有特定颜色分量的第二图像,并且至少部分地重叠在第一图像上,使其成为其特定颜色分量图像 颜色分量作为特定颜色分量,以及具有除了多个颜色分量中的特定颜色分量之外的颜色分量的图像; 颜色转换单元,其通过由所述分离单元分离的所述特定颜色分量以外的颜色分量执行所述图像的颜色转换; 以及组合单元,其将颜色转换图像与由颜色转换单元转换的特定颜色分量以外的颜色分量和由分离单元分离的特定颜色分量图像组合。
    • 38. 发明授权
    • Light emitting device, semiconductor device, and method of manufacturing the devices
    • US06525344B2
    • 2003-02-25
    • US09934058
    • 2001-08-21
    • Koichi Miyazaki
    • Koichi Miyazaki
    • H01L2715
    • H01L33/38H01L33/387
    • The invention provides a light emitting device and a semiconductor device each having improved characteristics by preventing occurrence of a damage caused by contact of a tool. On a substrate, an n-type semiconductor layer, an active layer, and a p-type semiconductor layer are stacked. On the p-type semiconductor layer, a p-side electrode is provided. The p-type semiconductor layer has a projected portion for limiting current in correspondence with a current injection area in the active layer. A projected portion is formed on the surface of the p-side electrode in correspondence with the projected portion for limiting current. On the surface of the p-side electrode, a protective portion is also provided in correspondence with the area other than the current injection area in the active layer. The top face of the protective portion is higher than that of the projected portion. With the configuration, contact of a tool or the like with the projected portion and its periphery can be prevented, so that the projected portion and its periphery such as the projected portion for limiting current and the current injection area in the active layer can be prevented from being damaged.
    • 39. 发明授权
    • Tetrapeptide derivative
    • 四肽衍生​​物
    • US6004934A
    • 1999-12-21
    • US190194
    • 1994-02-09
    • Kyoichi SakakibaraMasaaki GondoKoichi Miyazaki
    • Kyoichi SakakibaraMasaaki GondoKoichi Miyazaki
    • A61K38/00C07K5/02C07K5/027C07K5/06C07K7/02
    • C07K5/0205C07K7/02A61K38/00
    • A tetrapeptide derivative represented by the following formula or a salt thereof has a higher cytostatic activity than dolastatin 10, and is useful as an antitumor agent: ##STR1## wherein, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are the same or different and each represent a hydrogen atom, a lower alkyl group or an aralkyl group;Q represents ##STR2## or a group of -A.sub.2 -R.sub.7, wherein, A.sub.1 represents a direct bond or ##STR3## Y represents a hydrogen atom or --COR.sub.6, R.sub.5 represents a hydrogen atom, a lower alkyl group or an aralkyl group,R.sub.6 represents a hydroxyl group, a lower alkoxy group, an aralkyloxy group or ##STR4## wherein, R.sub.8 and R.sub.9 are the same or different and each represent a hydrogen atom, a lower alkyl group, a phenyl group or a 4- to 7-membered heterocyclic group containing one or two hetero atoms selected from S, O and N, or alternativelyR.sub.8 and R.sub.9 may combine together with the nitrogen atom to which they are bonded to form a 4- to 7-membered heterocyclic ring optionally further containing one hetero atom selected from S, O and N,A.sub.2 represents a direct bond or a lower alkylene group, andR.sub.7 represents a cycloalkyl group, an aryl group or an indolyl group,provided that the case is excluded where both R.sub.1 and R.sub.2 represent isopropyl groups, R.sub.3 represents a sec-butyl group, R.sub.4 represents a methyl group, and Q represents an .alpha.-(2-thiazolyl)phenethyl group.
    • PCT No.PCT / JP92 / 01005 Sec。 371日期1994年2月9日 102(e)1994年2月9日PCT PCT 1992年8月6日PCT公布。 出版物WO93 / 03054 日期:1993年2月18日由下式表示的四肽衍生物或其盐具有比多拉司他汀10更高的细胞生长抑制活性,可用作抗肿瘤剂:其中,R1,R2,R3和R4相同或不同, 表示氢原子,低级烷基或芳烷基; Q表示或一组-A2-R7,其中,A1表示直接键或Y表示氢原子或-COR6,R5表示氢原子,低级烷基或芳烷基,R6表示羟基, 低级烷氧基,芳烷氧基或其中R8和R9相同或不同,各自表示氢原子,低级烷基,苯基或含有一个或两个杂原子的4-至7-元杂环基团 从S,O和N,或者R8和R9可以与它们所键合的氮原子一起形成4-至7-元杂环,任选地还含有一个选自S,O和N,A2, 表示直接键或低级亚烷基,并且R 7表示环烷基,芳基或吲哚基,条件是排除R1和R2均表示异丙基的情况,R 3表示仲丁基,R 4表示 甲基,Q表示α-(2- 噻唑基)苯乙基。
    • 40. 发明授权
    • Tetrapeptide derivative having antitumor activity
    • 具有抗肿瘤活性的四肽衍生物
    • US5654399A
    • 1997-08-05
    • US498688
    • 1995-07-03
    • Kyoichi SakakibaraMasaaki GondoKoichi Miyazaki
    • Kyoichi SakakibaraMasaaki GondoKoichi Miyazaki
    • A61K38/00C07K5/02C07K5/027C07K5/06C07K7/02C07K5/00C07K7/00C07K17/00
    • C07K5/0205C07K7/02A61K38/00
    • A tetrapeptide derivative represented by the following formula or a salt thereof has a higher cyto-static activity than dolastatin 10, and is useful as an antitumor agent: ##STR1## wherein, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are the same or different and each represent a hydrogen atom, a lower alkyl group or an aralkyl group;Q represents ##STR2## or a group of --A.sub.2 --R.sub.7, wherein,A.sub.1 represents a direct bond or ##STR3## Y represents a hydrogen atom or --COR.sub.6, R.sub.5 represents a hydrogen atom, a lower alkyl group or an aralkyl group,R.sub.6 represents a hydroxyl group, a lower alkoxy group, an aralkyloxy group or ##STR4## wherein, R.sub.8 and R.sub.9 are the same or different and each represent a hydrogen atom, a lower alkyl group, a phenyl group or a 4- to 7-membered heterocyclic group containing one or two hetero atoms selected from S, O and N, or alternatively R.sub.8 and R.sub.9 may combine together with the nitrogen atom to which they are bonded to form a 4- to 7-membered heterocyclic ring optionally further containing one hetero atom selected from S, O and N,A.sub.2 represents a direct bond or a lower alkylene group, andR.sub.7 represents a cycloalkyl group, an aryl group or an indolyl group, provided that the case is excluded where both R.sub.1 and R.sub.2 represent isopropyl groups, R.sub.3 represents a sec-butyl group, R.sub.4 represents a methyl group, and Q represents an .alpha.-(2-thiazolyl)phenethyl group.
    • 由下式表示的四肽衍生物或其盐具有比多拉司他汀10更高的细胞静态活性,可用作抗肿瘤剂:其中,R1,R2,R3和R4相同或不同, 表示氢原子,低级烷基或芳烷基; Q表示或一组-A2-R7,其中A1表示直接键或Y表示氢原子或-COR6,R5表示氢原子,低级烷基或芳烷基,R6 表示羟基,低级烷氧基,芳烷氧基或其中R8和R9相同或不同,表示氢原子,低级烷基,苯基或4-7元 含有一个或两个选自S,O和N的杂原子,或者R8和R9的杂环基可以与它们所键合的氮原子一起形成4-7元杂环,任选地还含有一个杂原子 选自S,O和N,A2表示直接键或低级亚烷基,并且R 7表示环烷基,芳基或吲哚基,条件是排除其中R1和R2均表示异丙基的情况,R3 表示仲丁基,R 4表示甲基,Q表示 表示α-(2-噻唑基)苯乙基。